{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiczk3bcy7pmiisafzwhouru34v5smdbwdnyorguiuclniuuf6i22y",
    "uri": "at://did:plc:kpkcscbf2zshv7shqgqn45wn/app.bsky.feed.post/3mfjtwcdh4pt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicewazcdp7dvfn364654qdn4jahymcbfcfufv4aeojuzeu7z2hxyi"
    },
    "mimeType": "image/jpeg",
    "size": 1629
  },
  "path": "/story/384195/novo-nordisks-new-obesity-drug-fails-a-big-test.html",
  "publishedAt": "2026-02-23T05:51:00.000Z",
  "site": "https://www.newser.com",
  "textContent": "Novo Nordisk just learned its latest much-hyped obesity drug may not actually live up to the hype. Shares of the Danish pharma giant plunged 16% Monday after it reported that its experimental drug, CagriSema, did not match the weight loss achieved by Eli Lilly's rival drug in a direct comparison...",
  "title": "Novo Nordisk's New Obesity Drug Fails a Big Test"
}